PR Newswire
10 Feb 2023, 06:34 GMT+10
![]() |
BRISBANE, Australia, Feb. 10, 2023 /PRNewswire/ -- AcuraBio, a leading Australian biopharmaceutical contract development and manufacturing organization (CDMO), will provide a cGMP plasmid DNA CDMO service to the world using Cytiva's new process platform technology.
Jon Ince (left), General Manager, Australia & New Zealand, Cytiva and Guillaume Herry (right), CEO of AcuraBio, at the contract signing ceremony
AcuraBio expects to produce more plasmid DNA for its customers around the world using Cytiva's latest bacterial plasmid two-step purification protocol. The new protocol features single-use purification technology which delivers efficiency, high purity level outcome and sustainable process.[1]
Guillaume Herry, CEO of AcuraBio says: "We are very excited to implement Cytiva's latest technology especially because the access and production of plasmid DNA has been a bottleneck in the advanced therapy market. We intend to bring biotechs and biopharma companies a more high-quality plasmid DNA quicker than before to help the development of new therapies such as viral vectors and mRNA."
Jon Ince, General Manager, Commercial, Australia and New Zealand, Cytiva, says: "The adoption of Cytiva's FlexFactory configurable manufacturing train, within AcuraBio's assets will enable AcuraBio to advance and better serve their customers based with efficient and flexible cGMP manufacturing services that address the increasing demand for high quality therapeutics within the Australia and New Zealand region and beyond."
According to Research and Markets, the plasmid DNA manufacturing market size is estimated to be $525.12 million in 2022 and is expected to witness a CAGR of 13.87% from 2023 to 2033. A growing public understanding of cell & gene therapy and the surging number of patients choosing gene therapy as their treatment of choice are factors contributing to the market growth.[2]
To learn more about the plasmid DNA technology, please visit the Biotech Makers Webinar.
[1] Resources for calculated benefits for pDNA downstream process at 200 L scale |
[2] Plasmid DNA Manufacturing Global Market Report 2022: Surging Number of Patients Choosing Gene Therapy as Their Treatment to Fuel Growth |
About AcuraBio
AcuraBio Pty Ltd is one of Australia's most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.AcuraBio.com.
About Cytiva
At Cytiva, we believe the key to transforming human health is accessing life-changing therapies. That's why our nearly 10 000 associates in more than 40 countries are keenly focused on helping researchers, biopharma companies, and drug manufacturers to advance and accelerate therapeutics for people that need them. We're driven by their desire to achieve better flexibility, capacity, and efficiency in all facets of their work - all the way from discovery to delivery. Learn more at cytiva.com.
Media Contact:
AcuraBio
media@AcuraBio.com
Cytiva
Iris Zhao
meng.zhao@cytiva.com
Get a daily dose of Asia Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.
More InformationBANGUI, Central African Republic: Authorities from the Central African Republic have said that nine Chinese nationals were killed and two ...
MENINDEE, Australia: After recent floods and hot weather, millions of dead fish have washed up in southeastern Australia, which authorities ...
BOISE, Idaho: Under a bill passed by the Idaho Legislature thios with a veto-proof majority, the state will allow firing ...
SACRAMENTO, California: The state of California and generic drug manufacturer Civica have announced a 10-year partnership to produce affordable, state-branded ...
CHEYENNE, Wyoming: A Wyoming bill outlawing the use or prescription of medication abortion pills, which was passed by the state's ...
DENVER, Colorado: The Southern Nevada Water Authority has voted to accept a $2.4 million grant from the US Bureau of ...
MANILA, Philippines: An underwater robot from Japan has located a leaking fuel tanker, MT Princess Empress, which sank off the ...
NEW YORK, New York - A hike in official U.S. interest rates of 0.25 percent, and a jump in inflation ...
SEATTLE, Washington: In a memo to staff sent this week, Amazon CEO Andy Jassy said the company plans to cut ...
DETROIT, Michigan: Due to leaking brake hoses and windshield wiper arms that can break off, Ford is recalling more than ...
NEW YORK, New York - Wall Street continued its advance on Tuesday as investors continued to weigh up the health ...
WASHINGTON D.C.: The US State Department has issued a travel warning regarding dangerous fake pills sold at pharmacies in Mexico, ...